Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase
Open Access
- 1 April 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (4) , 581-586
- https://doi.org/10.1128/aac.34.4.581
Abstract
We studied the efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ceftriaxone in vitro and in experimental endocarditis due to an Escherichia coli strain producing an extended-spectrum beta-lactamase most similar to SHV-2, a new mechanism of resistance to broad-spectrum cephalosporins among members of the family Enterobacteriaceae. In vitro, ceftriaxone demonstrated an important inoculum effect (MICs were 2 and 256 micrograms/ml with 5 X 10(5) and 5 X 10(7) CFU of inoculum per ml, respectively). Sulbactam inhibited the beta-lactamase degradation of ceftriaxone and enhanced the killing by ceftriaxone with both inocula tested. In vivo, sulbactam (100 mg/kg every 8 h) or ceftriaxone (15 or 30 mg/kg every 24 h) alone were ineffective after a 4-day therapy. The addition of sulbactam to ceftriaxone (15 mg/kg) or to the ceftriaxone (15 mg/kg)-netilmicin (6 mg/kg every 24 h) combination produced a reduction of 2 log10 CFU/g of vegetation greater than that produced by therapy without sulbactam. The sulbactam-ceftriaxone (30 mg/kg) combination produced a reduction of almost 5 log10 CFU/g of vegetation greater than that produced by single-drug therapy (P less than 0.01), sterilized five of eight vegetations (versus none of seven for ceftriaxone [30 mg/kg] alone; P less than 0.05), and was as effective as the ceftriaxone (15 mg/kg)-sulbactam-netilmicin combination. We concluded that (i) SHV-2 production was responsible for ceftriaxone failure in vivo, probably because of the high inoculum present in vegetations; (ii) sulbactam used in a regimen which provided levels in serum constantly above 4 micrograms/ml and a vegetation/serum peak ratio of approximately 1:3 enhanced the activity of a broad-spectrum cephalosporin in a severe experimental infection; and (iii) the highest dose of ceftriaxone in combination with sulbactam was as effective as the lowest dose of ceftriaxone plus sulbactam plus an aminoglycoside.This publication has 18 references indexed in Scilit:
- Extended-spectrum beta-lactamasesAntimicrobial Agents and Chemotherapy, 1989
- Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditisAntimicrobial Agents and Chemotherapy, 1989
- Inducible -Lactamases: Clinical and Epidemiologic Implications for Use of Newer CephalosporinsClinical Infectious Diseases, 1988
- Synergy between clavulanic acid and newer β-lactams on nine clinical isolates of Klebsiella pneumoniae, Escherichia coli and Salmnella typhimurium resistant to third-generation cephalosporinsJournal of Antimicrobial Chemotherapy, 1988
- TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAEThe Lancet, 1987
- Ion pair high-performance liquid chromatographic assay for ceftriaxoneAntimicrobial Agents and Chemotherapy, 1987
- Emergence of Resistance During Therapy with the Newer -Lactam Antibiotics: Role of Inducible -Lactamases and Implications for the FutureClinical Infectious Diseases, 1983
- Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporinsJournal of Antimicrobial Chemotherapy, 1983
- Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatographyJournal of Antimicrobial Chemotherapy, 1983
- Beta-Lactamases: Determination of Their Isoelectric PointsAntimicrobial Agents and Chemotherapy, 1978